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Abstract
Interest in the composition of the intestinal microbiota and possibilities of its therapeutic modifications has
soared over the last decade and more detailed knowledge specific to the canine microbiota at different mucosal
sites including the gut is available. Probiotics, prebiotics or their combination (synbiotics) are a way of modify-
ing the intestinal microbiota and exert effects on the host immune response. Probiotics are proposed to exert
their beneficial effects through various pathways, for example production of antimicrobial peptides, enhancing
growth of favourable endogenous microorganisms, competition for epithelial colonisation sites and immune-
modulatory functions. Despite widespread use of pro-, pre- and synbiotics, scientific evidence of their beneficial
effects in different conditions of the dog is scarce. Specific effects of different strains, their combination or their
potential side-effects have not been evaluated sufficiently. In some instances, in vitro results have been promis-
ing, but could not be transferred consistently into in vivo situations. Specific canine gastrointestinal (GI) dis-
eases or conditions where probiotics would be beneficial, their most appropriate dosage and application have
not been assessed extensively. This review summarises the current knowledge of the intestinal microbiome
composition in the dog and evaluates the evidence for probiotic use in canine GI diseases to date. It wishes to
provide veterinarians with evidence-based information on when and why these products could be useful in pre-
venting or treating canine GI conditions. It also outlines knowledge about safety and approval of commercial
probiotic products, and the potential use of faecal microbial transplantation, as they are related to the topic of
probiotic usage.
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Introduction
Microorganisms are found abundantly in association
with mammalian hosts; in fact, the number of micro-
bial cells is around 10 times that of host cells (Gibson
& Roberfroid 1995), consisting of around 1000 times
more microbial genes (The Human Microbiome Pro-
ject; www.http://hmpdacc.org). The concept of the
microbiome was first suggested by Joshua Lederberg,
who coined the term ‘microbiome’ to ‘signify the
ecological community of commensal, symbiotic and
pathogenic microorganisms that literally share our
body space’ (Lederberg & McCray 2001). It is gener-
ally accepted that the term ‘microbiota’ (in the past
also referred to as microflora) is used to describe
bacterial communities on mucosal surfaces (with or
without luminal microorganisms) or on other body
sites (e.g. skin). Overlapping, but distinct, the term
‘microbiome’ is nowadays used to refer to the entire
genetic mass (‘genome’) of microorganisms. It is
mostly, but incorrectly, used to describe bacterial
genomic communities. One should probably refer
specifically to the ‘bacteriome’, ‘virome’(Mansfield
2015) or ‘mycobiome’ (Foster et al. 2013), respec-
tively, and use the term microbiome globally for all
microorganisms combined (ten Oever & Netea
2014). These microorganisms include eucaryotes,
archaea, bacteria, viruses and fungi. Living in such
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close contact, they usually are not harmful to the
host; but considered beneficial in most cases. For
example the intestinal microbiota supplies short-
chain fatty acids (SCFA) as nutrients for colonocytes
(Cummings 1981; Rerat et al. 1987; Cummings &
Macfarlane 1991).
In recent years, more and more research has
focused on characterising microbiota at different
body sites in people, leading to the Human Micro-
biome Project (The NIH HMP Working Group
2009); and considerable progress has also been made
in defining and understanding microbial communities
in small animals, especially as the availability of
large-scale genomic sequencing techniques.
Naturally, the detection of differences in micro-
biota characteristics or the microbiome composition
between healthy and diseased subjects has led to the
conclusion that modifying these microbial communi-
ties might have a beneficial effect on host health in
certain circumstances. This is where the application
of pre- or probiotics or their combination (so called
synbiotics) has been the focus of much attention;
especially in human and canine intestinal diseases
like inflammatory bowel disease (IBD) (Sauter et al.
2006; Ghouri et al. 2014; Rossi et al. 2014; Schmitz
et al. 2014, 2015a; Saez-Lara et al. 2015).
As probiotics are not usually defined as drugs, they
do not have to undergo any process proving their
efficacy in applications, diseases or even target spe-
cies. Hence, many medical claims have been made
regarding their beneficial effects, both in humans and
in animals. This review focuses on what is known
about the definitions, mechanisms of action and effi-
cacy of probiotics in different GI diseases in dogs,
and summarises these findings so that the reader can
make a better judgement about when and how to use
probiotics in small animal gastroenterology.
Composition of the gastrointestinal
microbial communities in dogs
The gastrointestinal microbiome in healthy dogs
Recently, high-throughput DNA sequencing tech-
niques have improved microbial identification in
small animals. Mostly, these techniques have been
applied to describe the phylogenetic structure and
functional capacity of the GI microbiome (Handl
et al. 2011; Swanson et al. 2011; Hooda et al. 2012).
Some studies have included mucosal samples or
intestinal content of different segments of the GI
tract (Suchodolski et al. 2009, 2010, Suchodolski
et al. 2012a), but most have focused on analysis of
faecal samples, as these are easier to obtain (Garcia-
Mazcorro et al. 2011; Handl et al. 2011, 2013; Swan-
son et al. 2011; Suchodolski et al. 2012b; Honneffer
et al. 2014; Minamoto et al. 2014a). This is important
when comparing studies with each other, as bacterial
populations have been shown to differ between dif-
ferent substrates and intestinal sites (Momozawa
et al. 2011).
In general, bacterial number and diversity increase
gradually along the GI tract (Suchodolski et al. 2005)
(Fig. 1). In the healthy canine stomach, total bacte-
rial load is comparably low (105 log10 16S rRNA
copy numbers), and mostly belong to Proteobacteria
(99.6% of obtained gene sequences) with only few
Firmicutes (0.3%) (Garcia-Mazcorro et al. 2012).
The predominant species are Helicobacter and Lac-
tobacillus spp. The healthy canine duodenal micro-
bial community as reported by one study to consist
of six primary phyla: Firmicutes (46.4% of obtained
16S rRNA gene sequences), Proteobacteria (26.6%),
Bacteroidetes (11.2%), Spirochaetes (10.3%)
Fusobacteria (3.6%) and Actinobacteria (1%)
(Xenoulis et al. 2008). Another study evaluated the
microbiota in the jejunum of healthy dogs, and iden-
tified Proteobacteria as the most abundant (46%),
followed by Firmicutes (15%), Actinobacteria (11.2),
Spirochaetes (14.2), Bacteroidetes (6.2%) and
Fusobacteria (5.4%) (Suchodolski et al. 2009)
(Fig. 1). Duodenal and jejunal ingesta samples con-
tained 22% and 10% of Lactobacillales respectively
(Xenoulis et al. 2008). Suchodolski et al. (2009) also
identified four additional phyla in the jejunum that
were not reported in dogs previously: Tenericutes,
Cyanobacteria, Verrucomicrobia and Chloroflex,
which were all present in low frequency (<0.1%)
(Suchodolski et al. 2009). The ileal ingesta from
healthy research dogs predominantly contained
Fusobacteria, Firmicutes and Bacteroidetes
(Suchodolski et al. 2008). This is significantly
© 2016 The Authors. Veterinary Medicine and Science Published by John Wiley & Sons Ltd.
Veterinary Medicine and Science (2016), , pp. –
S. Schmitz and J. Suchodolski2
different to the composition of the duodenal and
jejunal microbiome composition, as especially the
orders of Fusobacteriales (30%), and Clostridiales
(22%) with both Clostridium clusters XI and XIVa
were predominant in the healthy ileum. Also in con-
trast to duodenal and jejunal samples, ileal contents
had much lower proportions of Lactobacillus spp.
(1.4%). Whether these variations are true qualitative
and quantitative differences is hard to assess, as
some of them – especially between different studies
– are likely due to variations in the different DNA
extraction methods, differences in amplification pri-
mers, and sequencing platforms used (e.g. 454-pyro-
sequencing vs. 16S rRNA clone libraries). Colon
samples showed the co-dominant phyla of Fusobac-
teria, Bacteroidetes and Firmicutes (around 30%
each) in healthy dogs (Suchodolski et al. 2008). The
presence of Fusobacteria (108 cfu/ml of intestinal
content) also has been demonstrated using culture-
based techniques (Davis et al. 1977). The next abun-
dant order present was Clostridiales (18%), with
Clostridum cluster XIVa being the predominant
member (50%) (Suchodolski et al. 2008). This cluster
includes Eubacterium, Roseburia and Ruminococcus
spp., which are dietary fibre fermenters. Proteobacte-
ria, including E. coli-like organisms, were present in
low proportions (1.4%), whereas Lactobacillales
where present at levels similar to the jejunum (10%)
(Suchodolski et al. 2008). Results of the analyses of
the canine faecal microbiome indicated a predomi-
nance of the phyla Fusobacteria (24–40%), Bac-
teroidetes (32–34%), Firmicutes (15–28%),
Proteobacteria (5–6%) and Actinobacteria (0.8–
1.4%) (Xenoulis et al. 2008; Suchodolski et al. 2009;
Middelbos et al. 2010; Handl et al. 2011; Swanson
et al. 2011; Garcia-Mazcorro et al. 2012) (Fig. 1).
The effect of dietary intervention on the canine
gastrointestinal microbial composition
Even though some studies have provided evidence
that the administration of prebiotics/fibre in the diet
has the ability to manipulate the GI microbiota of
dogs (Spears et al. 2005; Beloshapka et al. 2013;
Fig. 1 Distribution of typical bacterial
phyla within different compartments of the
intestinal tract in dogs.
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Panasevich et al. 2014), there are some limitations.
Firstly, traditional plating techniques or qPCR to
quantify a limited number of bacteria (e.g. Lacto-
bacillus sp., Bifidobacterium sp., Clostridia, E. coli)
were mostly used (Spears et al. 2005; Strompfova
et al. 2012a). Second, most studies were performed
in healthy dogs, which make inferring results to dis-
eased dogs or animals susceptible to GI disturbances
(e.g. weanlings and geriatrics) difficult. Third, faecal
samples were analysed rather than mucosal biopsies
or ingesta (Spears et al. 2005; Verlinden et al. 2006;
Hang et al. 2012; Strompfova et al. 2012b). Lastly, a
wide range of prebiotic products and dosages have
been administered, making comparisons between
studies difficult. The authors of this review recently
analysed the faecal microbiome of dogs with food-
responsive chronic enteropathy (CE) before and
after 6 weeks of dietary intervention and compared
these to the faecal microbiome of healthy dogs
before and after they were switched to the same diet
used in the diseased dogs (a hydrolysed protein diet),
and could not detect a significant effect on microbial
composition or diversity attributed to the dietary
change (Schmitz et al., unpublished data). More
research using molecular sequencing techniques is
clearly needed to examine the effect of dietary inter-
ventions in healthy dogs and dogs with GI disease.
The canine gastrointestinal microbial
composition in disease
The invasion and/or colonisation of the GI tract with
specific pathogens may profoundly disturb the integ-
rity of the intestinal epithelial barrier (Viswanathan
et al. 2009). Several potential GI pathogens are
recognised in dogs, including Clostridium perfrin-
gens, Salmonella spp. and E. coli (Marks et al. 2002).
However, most of those are also recognised com-
mensals and have been isolated at similar frequen-
cies from dogs with and without signs of GI disease
(Marks & Kather 2003; Unterer et al. 2014; Busch
et al. 2015). Therefore, the cause and effect relation-
ship between those organisms and GI disease needs
to be interpreted with caution.
Non-specific alterations of the GI microbiota have
been regarded as a pivotal factor for the develop-
ment of acute or chronic GI disease. Several studies
have attempted to characterise the faecal microbial
composition in diarrhoeic dogs. In acute diarrhoea,
large-scale changes were observed, both with culture
and sequencing techniques. This included increased
abundance of Clostridium spp. (especially C. perfrin-
gens), E. coli, Lactobacillus and Enterococcus spp.
with concurrent reductions of those bacterial groups
that make up the majority of the normal colonic
microbiota, such as Faecalibacterium, Ruminococ-
caceae and Blautia spp. (Bell et al. 2008; Minamoto
et al. 2014b; Guard et al. 2015). In chronic diarrhoea,
significantly higher counts of Bacteroides sp. were
found using fluorescent in situ hybridisation analysis
(Jia et al. 2010). In a study evaluating a large group
of dogs with chronic diarrhoea using qPCR assays,
diseased dogs had significantly decreased abun-
dances of Fusobacteria, Ruminococcaceae, Blautia
spp. and Faecalibacterium spp. and significantly
increased abundances of Bifidobacterium spp., Lac-
tobacillus spp. and E. coli compared to healthy dogs
(Minamoto et al. 2014b).
In samples from dogs with IBD, microbiome
changes similar to the ones observed in people with
IBD were detected. A significantly reduced species
richness and higher proportion of Enterobacteri-
aceae were observed in duodenal brush samples from
dogs with IBD compared with healthy dogs (Xenou-
lis et al. 2008). Additionally, in duodenal mucosal
biopsies, a higher abundance of Proteobacteria and
lower amount of Clostridia were found in IBD com-
pared with healthy dogs (Suchodolski et al. 2010)
(Fig. 2). The analysis of faecal samples from dogs
with IBD revealed dysbiosis, with significantly lower
bacterial diversity, an increase in Gammaproteobac-
teria (i.e. E. coli) and decreases in Erysipelotrichia,
Clostridia and Bacteroidia (Minamoto et al. 2014a,
b).
Whether these changes are partially a cause or a
result of the aberrant immune reactions seen in the
GI tract in IBD remains a matter of debate, both in
people and in dogs. However, it is now suspected
that these bacterial changes are associated with
altered metabolic functions of the microbiota (e.g.
decrease in SCFA concentrations, altered amino acid
metabolism, changed in redox equilibrium, altered
© 2016 The Authors. Veterinary Medicine and Science Published by John Wiley & Sons Ltd.
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bile acid metabolism), and are therefore potentially
exacerbating the inflammatory state of the host (Hall
2011; Minamoto et al. 2014a; Guard et al. 2015).
Definition of probiotics, prebiotics
and synbiotics
Probiotics are most frequently defined as live
microorganisms, which when consumed in adequate
amounts confer a health benefit on the host (FAO/
WHO, 2002). However, in a lot of circumstances,
their health benefits are not strictly proven for a
given disease, application or host organism, but the
term probiotics is still used. It would be more appro-
priate to describe probiotics in small animals as live
microorganisms given with the intention of improv-
ing host health. They include exogenous and indige-
nous bacterial species that interact with various
cellular components within the host (see below).
Prebiotics are defined as selectively fermented
ingredients that result in specific changes in the com-
position and/or activity of the gastrointestinal micro-
biota, thus also being a benefit to the host organism
(Gibson et al. 2010; Roberfroid et al. 2010). Usually,
prebiotics are fibre compounds of different length
that pass undigested through the gastrointestinal
tract. These include disaccharides (lactulose, taga-
tose), oligo- or polysaccharides [fructo-oligosacchar-
ides (FOS), mannan oligosaccharides (MOS)
xylooligosaccharides, polydextrose, galacto oligosac-
charides] or long-chain prebiotics like inulin (Hughes
& Rowland 2001; Ogue-Bon et al. 2010; Roberfroid
et al. 2010; Koh et al. 2013).
Finally, synbiotics are preparations combining
both probiotics and prebiotics. This concept was first
introduced as ‘mixtures of probiotics and prebiotics
that beneficially affect the host by improving the sur-
vival and implantation of live microbial dietary sup-
plements in the gastrointestinal tract, by selectively
stimulating the growth and/or by activating the meta-
bolism of one or a limited number of health-promot-
ing bacteria, thus improving host welfare’ (Gibson &
Roberfroid 1995). The Food and Agriculture Organi-
zation of the United Nations (FAO) recommends
that the term synbiotic should be used only if the net
health benefit observed is synergistic.
Mechanisms of probiotic action
Probiotics can enhance mucosal health by several
proposed mechanisms, including displacement of
intestinal pathogens (Lee et al. 2003), production of
antimicrobial substances (Jones & Versalovic 2009),
enhancement of immune responses (Pagnini et al.
2010), and/or up-regulation of various metabolites
(Soo et al. 2008).
Probiotics can compete with potential pathogens
by interfering with their adherence to the intestinal
mucosa or by induction of mucus/mucin production
(Collado et al. 2007a). These mechanisms are
thought to be strain specific, with some strains having
increased adherence capabilities (e.g. L. rhamnosus
GG = LGG), and some strains being able to
increase the adherence of pathogens to intestinal
mucus (Collado et al. 2007b). In addition, probiotic
bacteria can produce various antimicrobial sub-
stances, for example fatty acids, lactic acid and acetic
acid (Saarela et al. 2000). Some Lactobacillus spp.
can decrease toxin gene expression and production
by Salmonella, E.coli or C. perfringens in vitro
(Medellin-Pe~na et al. 2007; Allaart et al. 2011;
Bayoumi & Griffiths 2012) or inactivate toxins by
Fig. 2 Distribution of bacterial phyla in
the duodenum of 14 dogs with inflamma-
tory bowel disease (IBD) and six healthy
dogs (based on: Suchodolski et al. 2012a,
b).
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production of proteases ex vivo (Castagliuolo et al.
1999). Immune modulation of the host organism –
especially intestinal epithelial cells (IECs)– might
occur through microbial cell wall components, their
metabolites or DNA (Oelschlaeger 2010; Thomas &
Versalovic 2010). The effects (again mostly shown
in vitro, but also in some animal models of inflamma-
tion) include maintenance and fortification of tight
junctions, prolonging the survival of IECs and induc-
tion of IgA and b-defensin production (Oelschlaeger
2010; Thomas & Versalovic 2010).
Intact, viable bacteria may be essential for probi-
otic effects, or these effects could be mediated by a
cell wall component or structurally diverse secreted
molecules, e.g. peptides, lipopeptides, lipopolysac-
charides (LPS), DNA, RNA (Laukova et al. 2004).
Several mechanistic studies show that key biological
signalling pathways like nuclear factor kappa B
(NFjB), mitogen-activated protein (MAP) kinases,
Akt/phosphatidyl inositol-3 kinase (PI3K) and per-
oxisome proliferated activator of transcription recep-
tor gamma (PPARc) are targets for probiotics or
their products both in vitro and in vivo (Thomas &
Versalovic 2010) (Fig. 3). These pathways can be
modified in different ways by individual probiotic
strains. This is clearly a strain-specific effect, as even
bacterial strains of the same species can alter cellular
responses differentially. For example, Lactobacillus
reuteri ATCC PTA 6475 can inhibit LPS-induced
tumour-necrosis factor alpha (TNFa) production
from myeloid cells in vitro through suppression of
the activator protein-1 (AP-1) pathway, whereas
another L. reuteri strain, DSM 17938, does not inhi-
bit LPS-induced TNFa production (Lin et al. 2009).
The details on cellular interactions of specific
probiotic strains have been summarised in several
Fig. 3 Proposed mechanisms of action of probiotics (modified from Thomas & Versalovic 2010).
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reviews (Oelschlaeger 2010; Thomas & Versalovic
2010; Fijan 2014; Vitetta et al. 2014) (figure 3).
Effects of probiotics on intestinal and overall
health have mostly been studied in humans and
rodent models of human disease (Culligan et al.
2009); much more limited data are available for
veterinary species (Callaway et al. 2008). Although
probiotics and prebiotics are administered to dogs
with increasing frequency, only few investigations
have evaluated the complex interplay of probiotics
with small animal host cells, immune function or
their effect on the intestinal microbial composition
(Garcia-Mazcorro et al. 2011). Most of these
in vivo studies in dogs were rather crude ex vivo
experiments (Sauter et al. 2005; Schmitz et al. 2013,
2014). In addition, most investigations specific for
companion animals have only studied the effects of
selected probiotic strains or probiotic mixtures on
the microbiome or other target effects, for example
cytokines (Sauter et al. 2005; Schmitz et al. 2013,
2014).
Microbial organisms commercially
used as probiotics in dogs in Europe
To date, four bacterial strains/products have been
examined by the European Food Safety Authority
(EFSA) for their safety and efficacy as probiotics or
feed additives in dogs. This includes two Enterococ-
cus faecium strains (E. faecium NCIMB 10415
E1705, E. faecium NCIMB 10415 E1707), Lacto-
bacillus acidophilus DSM 13241 25 and Bifidobac-
terium sp. animalis.
Both products containing an E. faecium strain had
already been approved for the use in farm animals at
the time approval for small animals was sought
(2004). For one of these strains, EFSA’s conclusion
was that enough information was provided to con-
sider it safe for the use in dogs and for humans hav-
ing contact with treated dogs (E. faecium NCIMB
10415 E1707). The other E. faecium, strain NCIMB
10415 E1705, was considered unlikely to represent a
hazard for the target species even when supplied in
overdose. It was shown to not favour the growth and
shedding of haemolytic and non-haemolytic E.coli in
dogs (and cats).
For the product containing Lactobacillus aci-
dophilus DSM 13241 25, EFSA did not establish a
safety concern, as the strain was sensitive to medi-
cally relevant antibiotics, with the exception of cipro-
floxacin. As no data on the effect of this probiotic on
shedding of intestinal pathogens in the dog were pro-
vided, and it was considered a potential respiratory
sensitiser, further data were requested by EFSA
before reaching a final conclusion (2004).
The latest probiotic strain assessed was Bifidobac-
terium animalis (2012). For this strain (no further
strain designation or details are available), the
requirements regarding the assessment of antibiotic
resistances were not met (as the strain was resistant
to clindamycin and the genetic basis of the resistance
could not be established). Based on two studies pro-
vided, the effect of B. animalis on GI-related param-
eters in dogs was considered of questionable
biological relevance and EFSA could not conclude
the efficacy of this product.
Apart from the strains mentioned above, other
probiotics or synbiotics are available as nutritional
supplements in dogs, both in Europe and in the
USA. Even though most products available in Eur-
ope to date contain the E. faecium strain NCIMB
10415 E1707, sometimes in combination with other
bacterial strains and different prebiotics, the prod-
ucts themselves have mostly not been specifically
approved or tested. On the other hand, E. faecium
NCIMB 10415 E1707 has been used most widely in
experimental settings, to assess effect on immune
function or gut health (see below). Other bacterial
strains available as over-the-counter supplements for
dogs contain different strains of Lactobacilli (L. aci-
dophilus, L. casei, L. plantarum, L. paracasei, L. lac-
tis, L. rhamnosus, L. salivarius), Bifidobacteria (B.
infantis, B. lactis, B. longum, B. bifidum), Bacillus
subtilis or coagulans and in some cases yeasts (Sac-
charomyces cerevisiae) or other fungi (Aspergillus
oryzae). However, limited data are available about
the safety and efficacy of these microorganisms/prod-
ucts or the health claims associated with them. Some
microorganisms other than E. faecium have been
tested as probiotics in experimental settings in dogs.
For example Saccharomyces boulardii was investi-
gated in a small pilot study presented as a congress
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abstract in dogs with IBD and protein-losing
enteropathy (P-LE); (Bresciani et al. 2014)]. It signif-
icantly improved clinical activity score and serum
albumin levels compared to the placebo-treated con-
trol dogs (Bresciani et al. 2014). Apart from single
bacterial strains tested in vitro (detailed below),
some single- and multi-strain probiotic products have
also been tested to a certain degree in a clinical set-
ting in dogs. For most single-strain studies, this is
limited to the use of E. faecium (Swanson et al. 2002;
Sauter et al. 2006; Strompfova et al. 2006; Schmitz
et al. 2015a). Several probiotic cocktails have been
used with variable effect. For example a mixture of
lactobacilli that showed promising ex vivo results
regarding creating a more tolerant microenviron-
ment in the gut, did not significantly improve out-
come when administered in a clinical trial (Sauter
et al. 2006). In another study, strains from a product
approved for the use in people (VSL#3) have been
administered to dogs with IBD leading to some clini-
cal and immunological improvement (Rossi et al.
2014). This includes four Lactobacilli (L. acidophilus,
L. plantarum, L. paracasei, L. delbrueckii ssp. bulgar-
icus), three Bifidobacteria (B. breve, B. longum, B.
infantis) and Streptococcus thermophilus.
Testing of microbial strains for their
qualifications as probiotics in dogs
Several bacterial strains, mostly lactic acid produc-
ing bacteria (LAB) isolated from canine faeces,
some originally used in other species or people,
have been tested for their probiotic potential
in vitro (but are currently not available in com-
mercial products). Studies have especially focused
on the survival properties of these strains at low
pH (to mimic passage of the stomach), to resist
degradation by bile acids in the small intestine,
their adhesion properties to intestinal mucus and
their potential to either produce antimicrobial
peptides or to inhibit in vitro growth of pathogens
(mostly E. coli and Salmonella ssp.). Some other
functional and genetic properties (e.g. fermenta-
tion of carbohydrates, immune-modulating effects)
have also been assessed. These studies and their
main outcome are summarised in Table 1.
Very little is known about the appropriate dose of
probiotics in general in small animals, let alone in
specific diseases. Survival characteristics of probiotic
strains (especially E. faecium) have been tested
in vitro and in vivo, that is in low environmental pH
(mimicking gastric passage), the presence of bile,
adhesion to mucus, recovery of live bacteria from
faeces of dogs after oral administration (Laukova
et al. 2004, 2008; Strompfova et al. 2004a;
Marcinakova et al. 2006). Overall, it is not entirely
clear if probiotic survival is even necessary for a ben-
eficial effect, or if, for example their DNA is suffi-
cient (Kant et al. 2014). There is some evidence that
even non-viable probiotic bacteria can cause immune
modulation in the host (Zhong et al. 2012). Also,
there is very little information regarding possible
interactions of strains in multi-strain formulations;
even though some studies in experimental rodents or
humans show a synergistic effect on the measured
outcome (Baillon et al. 2004). The effect of formula-
tion (liquid, capsule, in-feed) or natural sources of
potential probiotics (yoghurt, raw green tripe, fer-
mented plant material) is mostly unexplored to date.
Some preliminary data on the effect of feeding raw
meat, prebiotic fibre and yeast cell wall extract on
the composition of faecal microbiota are available
(Beloshapka et al. 2013). Changes depending on the
meat protein source (chicken vs. beef) were less evi-
dent, but minor changes in faecal microbiota compo-
sition were seen when prebiotics were added (e.g.
greater presence of fusobacteria, lower abundance of
Faecalibacterium). The significance of these observed
changes, however, remains unclear, especially as this
study was performed in healthy dogs. Furthermore,
most studies evaluated faecal samples and noticed
only minor changes. However, recent studies suggest
that probiotic mixtures (i.e. VSL#3) are able to
induce major changes in the ileal mucosa-adherent
microbiota in colitic mice and also dogs with chronic
enteropathies (Mar et al. 2014; White et al. 2015).
Quality control is also an issue with probiotic
products. As they are usually classified as nutritional
supplements, quality control as for drugs is not leg-
ally required. Again, no large amount of data are
available on the quality, shelf-life, etc., of commer-
cially available probiotics. One study has assessed
© 2016 The Authors. Veterinary Medicine and Science Published by John Wiley & Sons Ltd.
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microbial components of dog food claiming to con-
tain probiotics (Weese & Arroyo 2003). None of the
19 commercial diets contained all the claimed organ-
isms, whereas one or more of the listed components
could be isolated from around 50% of samples. Ele-
ven samples contained additional, related organisms
and more than 25% of tested diets showed no rele-
vant bacterial growth. To the authors’ knowledge, no
published study has so far assessed whether the
claimed bacterial quality or quantity in probiotic
nutritional supplements is according to label claims.
The effect of probiotics on selected
parameters in healthy dogs
Enterococcus faecium
Interestingly, even though E. faecium is the most
widely used probiotic strain in small animals, not
many studies have focused on its safety or effects
when administered to healthy dogs. In a study from
2003 performed at the Nestle Purina Product Tech-
nology Centre, puppies from different popular dog
breeds were assigned one of two different diets after
weaning (Benyacoub et al. 2003). One of the diets
was a commercial, complete dog food with no sup-
plements (control group), the other was the same
diet with a stable encapsulated form of E. faecium
10415 SF68 in a dosage of 5 9 108 cfu day1 added
(treatment group). Main outcome measures included
determination of total faecal IgA, total and vaccine-
specific immunoglobulin gamma (IgG) and IgA
serum concentrations, and quantification of circulat-
ing lymphocyte subsets by flow cytometry. Food
intake, weight and routine laboratory parameters
(complete blood count, serum biochemistry) were
also evaluated. At the end of the study period
(1 year), puppies consuming the test diet had signifi-
cantly higher total faecal and serum IgA levels (but
not serum IgG) compared to the control group. In
addition, vaccination-associated IgA and IgG for
canine distemper virus were also significantly higher
in E. faecium-treated puppies compared to controls
from week 31 on. All other parameters were not dif-
ferent between groups. This study concluded that E.
faecium can enhance specific immune functions inT
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young dogs (Benyacoub et al. 2003), but the clinical
relevance is questionable as measured endpoints do
not necessarily correlate to a ‘healthier’ intestine.
Overall, evidence justifying the use of E. faecium
under these conditions is limited.
In the second study investigating effects of E. fae-
cium on healthy dogs, the strain used (E. faecium
EE3) was isolated and enumerated from a commer-
cially available canine food (Marcinakova et al. 2006).
It was orally administered to healthy adult dogs of dif-
ferent breeds and ages for 1 week at a daily dosage of
2–3 9 109 cfu dog1. Faecal cultures and blood sam-
ples for routine biochemistry values were obtained
before and at the end of the treatment period, as well
as 1, 2 and 3 months after cessation of probiotic
administration. E. faecium treatment did not cause any
clinical side-effects. The strain persisted in faeces for
3 months after cessation of treatment (reaching aver-
age concentrations of 6.83  0.95 log cfu g1). Total
concentration of LAB increased, and Pseudomonas-
like bacteria and Staphylococcus spp. decreased in fae-
cal samples, but the abundance of E. coli was not influ-
enced. Total serum lipids and protein decreased in
most dogs with treatment, with cholesterol being
within the reference range of all dogs at the end of the
treatment period. This study, therefore, inferred a ben-
eficial influence of E. faecium on canine health, possi-
bly even in obesity, even though obese animals were
not examined in the study, and the beneficial effect of
normalisation of cholesterol is questionable
(Marcinakova et al. 2006). In addition, this is the only
study that has shown long-term persistence of orally
administered probiotics in dogs, there was a lack of a
control group and it is not entirely clear how the strain
identification was performed; hence the results of this
study have to be interpreted with caution. Also, for
both of these studies, it has to be questioned if the defi-
nition of probiotics has been fulfilled using E. faecium,
as a relevant benefit of increased faecal IgA, elevated
vaccine-associated titres or ‘lowered’ cholesterol has
not been demonstrated.
Lactobacilli and bifidobacteria
A number of studies have investigated the safety and
effect of single-strain LAB preparations in healthy
dogs. For example effects on measured outcomes of
the administration of L. acidophilus have been con-
troversial. In one study, its administration (L. aci-
dophilus DSM13241) to adult dogs was associated
with changes in haematological and immunological
parameters (increased red blood cells [RBC], Hct,
haemoglobin, neutrophils, monocytes and serum
IgG, reduced RBC fragility and serum NO concen-
trations) of questionable clinical relevance (Baillon
et al. 2004). In another study, the supposedly benefi-
cial changes observed in the composition of the
microbiota and faecal metabolites was more attribu-
ted to the addition of prebiotic FOS than to L. aci-
dophilus NCFM itself (Swanson et al. 2002).
L. fermentum has been tested by the same group
in two studies (Strompfova et al. 2006, 2012a). This
LAB (L. fermentum AD1) was originally isolated
from faeces of a healthy dog (6-year-old Tibetan Ter-
rier) and was shown to have good in vitro survival at
a pH of 3.0 for 3 h (86.8%), and in the presence of
1% bile (75.4%), as well as good adhesion properties
to canine and human intestinal mucus, and no unac-
ceptable antimicrobial resistance (Strompfova et al.
2006). It was orally administered to 15 healthy dogs
of various breeds at a dose of 3 9 109 cfu dog1 for
7 days. Significant increases of faecal lactobacilli,
enterococci, and serum total protein, total lipids and
reduction in blood glucose were noted. In a follow-
up study, the strain was administered in freeze-dried
form to healthy dogs, and was shown to persist short-
term in the GI tract and to increase SCFA concen-
trations. Additionally, a reduction in Clostridia and
Gram-negative bacteria (coliforms, Aeromonas,
Pseudomonas) were also noted by faecal culture
(Strompfova et al. 2012a). In the study, this was
implied as a desired outcome, however, as this is a
culture-based approach and some members of Clos-
tridia have been identified as part of the normal ben-
eficial gut flora (see above), deductions regarding gut
health are difficult to make from these data. More
detailed investigations to evaluate whether this pro-
biotic strain reduces specifically the potential patho-
gen C. perfringens rather than Clostridia in general
would be needed.
Lactobacillus animalis LA4 (isolated from the fae-
ces of a healthy adult dog) was tested in vitro and
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in vivo in nine dogs (freeze-dried, given for 10 days).
On day 11, cultured faecal lactobacilli concentrations
were increased and enterococci reduced compared to
the beginning of the trial, hence this strain was con-
cluded to have some probiotic properties (Biagi et al.
2007). However, this conclusion is nearly impossible
to make, as semi-quantitative culture was the only
outcome assessed and there was no control group.
A more recent study used a genetically engineered
strain of Lactobacillus casei (no further strain desig-
nation available), capable of producing biologically
active canine granulocyte macrophage colony stimu-
lating factor, and investigated its properties as a pro-
biotic for dogs (Chung et al. 2009). It was
administered at 1 9 109 cfu day1 for 7 weeks.
Treated dogs showed increased monocyte counts,
serum IgA and canine coronavirus-specific vaccina-
tion-associated IgG compared with dogs fed a regu-
lar diet without probiotic supplements and dogs
receiving a non-engineered strain of L. casei (Chung
et al. 2009). The clinical relevance of this finding and
the safety and efficacy of administration of this strain
remains open.
Different strains of Bifidobacterium animalis
[AHC7; (Kelley et al. 2010); and an unspecified
strain isolated from dog faeces (Strompfova &
Laukova 2014)], were investigated by the same
group and found to not cause any undesirable
effects. Their administration to healthy dogs
increased the number of cultured LAB, but low-
ered the count of coliform bacteria in canine fae-
ces. Other faecal and serum parameters as well as
the phagocytic activity of peripheral blood leuco-
cytes (especially neutrophils) were improved in
treated dogs compared with the untreated control
group. These effects could be detected several
weeks after the treatment had been ceased
(Strompfova et al. 2014), but again their relevance
remains unclear, especially as methods used were
rather crude assessments of immune function.
Overall data on improving gut health or immuno-
logical status in dogs using lactobacilli or bifidobacte-
ria are not compelling, especially in the light of the
fact that it is not known if increasing certain bacterial
phyla is correlated with improved GI function or a
lower incidence of diarrhoeic diseases.
Bacilli
Bacilli are thought by some authors to represent
superior probiotics to LABs, as they can sporulate
and thus be more resistant to environmental stress
and low pH (Biourge et al. 1998; Felix et al. 2010).
However, mere survival might be not the most
important feature of a probiotic, and they all need to
be tested for their benefit in clinical situations. In
some European countries, probiotic products con-
taining Bacilli are available as nutritional supple-
ments for humans and animals (Biourge et al. 1998).
They have been shown to have beneficial effects on
the survival of mice infected with Klebsiella pneumo-
niae and on the breeding performances of a number
of production animals (Biourge et al. 1998). Bacillus
CIP 5832 was found to be persistent when added to
canine food and when exposed to expansion-extru-
sion and drying experiments. They were also able to
survive the canine GI tract, however, did not seem to
persist, as they disappeared from faeces 3 days after
cessation of administration (German et al. 2000).
Only one study found that Bacillus subtilis C-3102
can improve faecal texture and odour in dogs due to
a decreased content of faecal ammonia (Felix et al.
2010). Once again, the clinical relevance of this find-
ing and the justification of calling bacilli ‘probiotics’
in this situation is highly questionable and the usage
of Bacilli as probiotics cannot be recommended.
Probiotic mixtures
Mixtures of probiotics used in healthy dogs have
been of variable composition; in addition, outcome
measures were different, mainly also due to the
availability of different techniques to assess changes
in microbial communities. One study administered
five potentially probiotic LAB strains (L. fermentum,
L. salivarius, Weissella confuse, L. rhamnosus and L.
mucosae) to five permanently fistulated Beagle dogs
for 7 days (Manninen et al. 2006). Denaturing gradi-
ent gel electrophoresis (DGGE) demonstrated that
the LAB modified the dominant indigenous jejunal
LAB microbiota. All strains were undetectable
7 days after administration ceased and effects were
transient. In another study (Garcia-Mazcorro et al.
13
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2011), seven strains of LAB (E. faecium, S. salivarus
ssp. thermophilus, B. longum, L. acidophilus, L. casei
ssp. rhamnosus, L. plantarum, L. delbrueckii ssp. bul-
garicus) were administered to 12 healthy dogs and
faecal microbial communities were assessed using
DGGE gels, 16S rRNA gene libraries, quantitative
PCR and 16S rRNA gene 454-pyrosequencing. Pro-
biotic species were detectable in 11/12 dogs during
product administration, but not before or after.
Abundances of Enterococcus and Streptococcus spp.
were significantly increased. However, on pyrose-
quencing, no changes in the major bacterial phyla
were observed. This study concluded that the pro-
duct was well tolerated and did not cause any clinical
side-effects. Administration of the product resulted
in increased abundance of the probiotic genera, but
this was not sufficient to cause significant changes in
the overall microbiome structure (Garcia-Mazcorro
et al. 2011) and certainly cannot automatically be
inferred to convey a health benefit.
Finally, a synbiotic consisting of E. faecium SF68,
Bacillus coagulans, L. acidophilus and several prebi-
otics (FOS, MOS) and vitamins (B3, B6) was admin-
istered in a placebo-controlled trial to healthy
trained sled dogs, and changes of the composition of
the faecal microbiota assessed using quantitative
PCR and tag-encoded FLX 16S rDNA amplicon
pyrosequencing (Gagne et al. 2013). Alterations in
the faecal microbiome observed included a rise in
Lactobacillaceae and an increased faecal butyrate
concentration across all dogs. Faecal scores also
improved compared with the control group at
5 weeks (Gagne et al. 2013). Whether these findings
are correlated, beneficial to the host or even only
incidental, remains unclear.
Use of probiotics in small animal
gastrointestinal diseases
Infectious and non-infectious acute diarrhoea
Overall, it seems that – possibly depending on the
probiotic strain or mixture used – there is some merit
in the use of probiotics in acute infectious canine GI
diseases. Administration of the probiotic mixture
VSL#3 in a randomised manner to puppies with con-
firmed parvoviral enteritis lead to an increased per-
centage of surviving dogs (90% in probiotic group vs.
70% in the non-probiotic group), and a more rapid
improvement of clinical scores and leucocyte/lym-
phocyte counts (Arslan et al. 2012). In another study,
there was a significant reduction in Ancylostoma
eggs shedding in 10 dogs treated with a mixture of
LABs (L. acidophilus ATCC 4536, L. plantarum
ATCC 8014 and L. delbrueckii UFV H2B20) for
28 days compared with an untreated control group
(Coe^lho et al. 2013). Similar results could not be
achieved for the treatment of canine giardiasis with
E. faecium SF68: after 6 weeks of treatment no dif-
ferences in cyst shedding, faecal antigen shedding,
faecal IgA or leucocyte phagocytic activity were
observed between treated and untreated dogs (Simp-
son et al. 2009).
Other forms of acute diarrhoea in dogs in which
probiotics have been administered include stress-
associated (e.g. kennelling stress), antibiotic-induced
and idiopathic diarrhoea. Results are variable,
depending on the probiotic strain and the dog popu-
lation evaluated. Using E. faecium SF68, there was
no effect on kennel stress-associated diarrhoea,
which might partially be due to the low prevalence
of diarrhoea in this study (Bybee et al. 2011). Faecal
scores were significantly improved in dogs undergo-
ing kennelling stress when supplemented with Bifi-
dobacterium animalis AHC7 compared with an
untreated control group (Kelley et al. 2012). The
same strain was able to significantly reduce the time
to resolution of clinical signs and the number of dogs
receiving metronidazole in a study of acute idio-
pathic diarrhoea (dose of 2 9 1010 cfu day1) (Kel-
ley et al. 2009). Similar responses were seen in a
study of acute gastroenteritis using a probiotic mix-
ture of L. acidophilus, Pediococcus acidilactici, B.
subtilis, B. licheniformis and L. farciminis (Herstad
et al. 2010). Recovery time was significantly reduced
(mean 1.3 days, 95% CI: 0.5–2.1 days) compared
with untreated controls (mean 2.2 days, 95% CI:
1.3–3.1 days) with a comparably large dose of
4.2 9 109 cfu/10 kg three times daily (Herstad et al.
2010). Inactivated bacterial compounds as part of an
‘enterovaccine’ might also be useful in treating recur-
rent self-limiting episodes of diarrhoea (e.g. stress-
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related) in dogs. One commercially available prepa-
ration (deactivated whole bacteria and lysates of E.-
coli, Bacillus pumilus, Morganella morganii,
Alcaligenes faecalis, Shigella flexneri, Bacillus sub-
tilis, Enterococcus faecalis and Proteus vulgaris)
reduced the number of diarrhoea episodes and sever-
ity in five of six treated dogs (Cerquetella et al.
2012). There were no control dogs in this pilot study,
hence the exact potential of this inactivated bacterial
mixture needs to be evaluated by further clinical
studies. Interestingly, administration of Saccha-
romyces boulardii to dogs with experimental lin-
comycin-induced diarrhoea could prevent, but not
treat this condition (Aktas et al. 2004).
Chronic diarrhoea
Similar to people, the pathogenesis of chronic inflam-
matory conditions of the GI tract in dogs (e.g. CE/
IBD) is assumed to be due to an aberrant response
of the immune-system to the luminal or adherent
intestinal microbiota (Sartor 2006; Hall & German
2010). There is ample evidence of immune dysregu-
lation, even though the exact type of inflammatory
response and pathogenesis has not been elucidated
yet (German et al. 2000; Peters et al. 2005; Jergens
et al. 2009; Schmitz et al. 2012). Several studies have
shown that there are also alterations of the intestinal
microbiome present in canine CE/IBD (Suchodolski
et al. 2012a, b). Hence, there have been several
attempts to influence the composition of the micro-
biota in those dogs to alleviate clinical signs; partially
using probiotics that had already shown to have
some immune-modulatory properties in in vitro or
ex vivo studies (Sauter et al. 2005, 2006; Schmitz
et al. 2013, 2014). E. faecium NCIMB 10415 E1707
has been assessed as a single-strain treatment in dogs
with food-responsive disease (FRD) and found to
have no effect on clinical activity score, histology
scores or duodenal and colonic gene expression of
selected genes associated with specific T-helper lym-
phocyte lines (Schmitz et al. 2015b). In addition,
there was also no effect of E. faecium treatment on
gene or protein expression of inflammasome com-
pounds (Schmitz et al. 2015b). More promising
results could be achieved by using probiotic mixtures
in FRD dogs: A combination of LAB (L. acidophilus
and L. johnsonii) reduced duodenal interleukin (IL)-
10 and colonic interferon gamma (IFNc) mRNA
levels and the number of faecal Enterobacteriaceae,
whereas numbers of Lactobacillus spp. increased.
Clinical improvement was noted to similar levels in
dogs receiving the LAB cocktail compared with dogs
treated with diet alone (Sauter et al. 2005).
Additionally, a probiotic mixture with VSL#3
strains formulated for pets (SIVOYTM; details above)
was used in dogs with idiopathic IBD and compared
to a treatment regimen with metronidazole and pred-
nisolone in an open-label trial (Rossi et al. 2014).
Clinical activity, duodenal histology scores and CD3+
lymphocytes in the intestinal tissue decreased post-
treatment in both groups. However, FoxP3+ cells (a
marker of regulatory T-helper lymphocytes [Tregs])
increased significantly after treatment only in the
dogs treated with VSL#3 strains. Also, transforming
growth factor beta (TGFb)+ cells (most likely Tregs)
increased in both groups after treatment, but to a
greater magnitude in probiotic treated dogs. There
was some effect of the probiotics on expression of
tight junction proteins, with occludin being signifi-
cantly elevated in healthy control dogs and dogs trea-
ted with probiotics compared with IBD dogs.
Microbiome analysis based on quantitative PCR
revealed a reduced abundance of Faecalibacterium
and Turicibacter in dogs with IBD at the start of the
trial, with a significant increase in Faecalibacterium
observed in the animals treated with VSL#3 strains
(Rossi et al. 2014). This is noteworthy, as Faecalibac-
terium prausnitzii has been advocated as an anti-
inflammatory commensal bacterium in people
(Miquel et al. 2013) and is of lower abundance in
intestinal contents or faecal samples from human
and canine IBD patients (Suchodolski et al. 2012b;
Fujimoto et al. 2013).
Saccharomyces boulardii yeasts have been admin-
istered to dogs with CE/PLE and healthy control
dogs in the small pilot placebo-controlled double-
blinded clinical trial mentioned above at
1 9 109 cfu kg1 body weight BID for 10 days
(Bresciani et al. 2014). Dogs with CE or PLE addi-
tionally received standard medical treatment consist-
ing of diet, antibiotics and/or immunosuppressive
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drugs. S. boulardii was not detected in faecal samples
of healthy dogs before treatment started, but was
present after 1 day of supplementation, reached
highest levels after 5 days (10 9 107 cfu g1) and
was eliminated 4 days after withdrawal of treatment.
In dogs with CE, clinical score improved signifi-
cantly, and in dogs with PLE serum albumin values
increased significantly compared with placebo treat-
ment. Duodenal endoscopic and histology scores
were not different before and after treatment in any
of the dogs. The study concluded that S. boulardii
can be safely administered to dogs and it might be
useful as an adjunctive treatment in CE and PLE
(Bresciani et al. 2014). However, as it is a small study
and has not been fully published yet, awaiting of the
full results and further research into the usefulness of
S. boulardii as a potential probiotic is warranted.
Faecal microbial transplants
Administration of single-strain or even multi-strain
probiotic products might have a limited ability to
influence the composition of the intestinal micro-
biome permanently, especially given the fact that the
microbiome consists of hundreds of microbial spe-
cies. Based on the assumption that a more complex
change is needed in certain conditions (e.g. Clostrid-
ium difficile infection or IBD), there have been
attempts of transferring the intestinal microbiota
from one subject to another. This has been termed
faecal microbial transplantation (FMT), microbiome
restorative therapy or faecal bacteriotherapy. In
human medicine, FMT has been mostly performed
for recurrent C. difficile infection. Two reviews show
that it is safe and effective in 83–92% of human
patients, which achieved full resolution of clinical
signs (Gough et al. 2011; Guo et al. 2012). Limited
clinical data are available evaluating the use of FMT
for IBD in humans, but pilot studies suggest that the
response rate to FMT in chronic intestinal inflamma-
tion is much lower compared with C. difficile infec-
tion (Colman & Rubin 2014). Experience in small
animals regarding the safety and efficacy of FMT is
scarce and anecdotal. Two congress abstracts report
some preliminary findings in dogs. One is a case
report of an ongoing study (not published), where a
dog with eosinophilic IBD of 2 years duration and
moderate clinical signs with conventional therapy
was given the FMT by enema, with 45 min retention
time. Faecal consistency improved within 24 h and
the dog had been clinically well at the time of the
report (3 months after treatment). Next-generation
16S rRNA gene sequencing of the faecal microbiome
revealed that by day 2 after FMT, the dogs’ faecal
sample clustered with the donor, not the own base-
line sample, and species richness increased compared
to pre-treatment values (Weese 2013). The other
abstract reports the use of FMT in 8 dogs with
refractory presumptive Clostridium perfringens-asso-
ciated diarrhoea (Murphy et al. 2014). Again, it was
administered as an enema (1–3 transplants per dog).
All dogs had immediate resolution of their diarrhoea
and 6/8 dogs were negative on follow-up PCR panels
for C. perfringens alpha toxin. As mentioned before,
C. perfringens can be part of the normal intestinal
flora in dogs, hence it remains unclear if the detected
C. perfringens was really the cause of the diarrhoea
or rather a part of intestinal dysbiosis (Minamoto
et al. 2014b). If that had been the case, it needs still
to be critically assessed whether the FMT addressed
Clostridiosis, even if the microbiome changes suggest
an improvement of faecal dysbiosis. Both authors of
the unpublished conference abstracts conclude that
FMT should be considered as a treatment option in
dogs failing other therapeutic options (Weese 2013;
Murphy et al. 2014) and anecdotal evidence of its
usefulness is increasing in the veterinary community.
Prospective studies in large cohorts of dogs are
needed to properly address the usefulness of FMT in
defined GI diseases in dogs.
Conclusions
The microbiota on mucosal surfaces, especially the
GI tract, in dogs is complex. The composition varies
from site to site and there is some evidence that
changes in the composition of the microbiota/micro-
biome are associated with certain diseases. However,
analysis of the canine GI and faecal microbiota com-
position, its function, production of metabolites and
immunological properties is far from complete, even
though data on the microbiome are accumulating.
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Accordingly, overall knowledge of the best charac-
teristics of a canine microbial commensal or probi-
otic is patchy and most assumptions about their best
properties are derived from human studies. There
are some bacterial strains that show promise as
potential probiotics, especially LAB. However, the
effects of the most commonly used strain (E. fae-
cium) are still not well understood, particularly in
diseased dogs. It is challenging to compare outcomes
of different studies, both in healthy and in diseased
dogs, as there is huge variation in the probiotics used
(single-strain, multi-strain, type of microorganism),
their dosage, application form and frequency. Mea-
sured outcomes are also not consistent. Overall, it
seems to the authors that E. faecium tends to be
more suitable for acute and/or infectious forms of
diarrhoea; as there is some evidence it produces a
more pro-inflammatory rather than anti-inflamma-
tory reaction (Schmitz et al. 2014, 2015b); whereas
some lactobacilli and bifidobacteria show more pro-
nounced immune-regulatory functions. Intriguingly,
especially a combination of LABs (VSL#3) used in
human medicine to prevent relapse of Ulcerative
Colitis has some promise in treating chronic entero-
pathies in dogs and in creating a more anti-inflamma-
tory local environment (Rossi et al. 2014). It is
interesting to note that even in well-defined infec-
tious diseases like parvovirosis or parasitic infesta-
tion, some probiotics show a beneficial effect. The
mechanism behind this is not well understood and
further research is warranted. It is clear from studies
in people and experimental rodents, that the
immunological outcome depends on both the bacte-
rial strain or even subspecies – probably in a dose-
dependent manner (Weese & Anderson 2002;
Evrard et al. 2011; Garcia-Mazcorro et al. 2011) –
and the respective host’s immune response. In
humans, probiotics have been classified into ‘pro-
inflammatory’ and ‘anti-inflammatory’ by some
authors, depending on their major properties (Shida
et al. 2011). Because of this, careful assessment of
potential probiotics in the target species and disease
– possibly both in vitro and in vivo – is necessary to
judge their full potential. Some authors even propose
to test all probiotics in vitro or in tissue explants first,
before performing in vivo trials (Tsilingiri et al.
2012). However, this might not always be possible in
veterinary medicine.
There should also be a consideration that bacteria
might not always be the most appropriate probiotics.
We know virtually nothing regarding the fungal or
even viral composition of the normal intestinal tract
or other mucosal surfaces in dogs (Foster et al.
2013). There is some evidence that yeasts like Sac-
charomyces boulardii might be valid alternative pro-
biotics and need more detailed investigations.
Furthermore, an emerging field is the research into
bacterial metabolites (e.g. indole, acetate) that may
potentially serve as postbiotics.
Faecal transplantation is an interesting option to
treat both acute and chronic diarrhoea in dogs, how-
ever, much more needs to be understood regarding
its best performance, safety and usefulness, before it
can be recommended as a routine treatment.
In summary, more work needs to be done to
understand the complex interplay between potential
probiotics and their host environment. Very careful
investigations into mechanisms of action and
detailed measured outcomes will help to understand
which probiotic is useful in which condition, and
which changes of the intestinal microbiome are nec-
essary to achieve clinical remission of both acute and
chronic conditions.
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